secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0000950170-25-105807
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics receives Nasdaq MVLS deficiency notice; 180-day cure period to Feb 2026
--------------------------------------------------------------------------------

- Nasdaq notified FibroBiologics on Aug 4, 2025 that its MVLS fell below the $35M minimum for continued listing.
- Company has until Feb 2, 2026 to regain compliance by having MVLS close at $35M+ for 10 consecutive business days.
- No immediate impact on listing; stock continues trading on Nasdaq Capital Market under symbol FBLG.
- If compliance is not regained by Feb 2, 2026, Nasdaq may initiate delisting, subject to appeal.
- Company will monitor MVLS and consider available options to address the deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000095017025105807/0000950170-25-105807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000095017025105807/fblg-20250725.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer